Invasive aspergillosis
diseaseOn this page
Summary
Invasive aspergillosis (MONDO:0000240) is a disease and 53 clinical trials. Top therapeutic interventions include posaconazole, voriconazole, and amphotericin b. A subtype of pulmonary aspergilloma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 53
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | invasive aspergillosis |
| Mondo ID | MONDO:0000240 |
| DOID | DOID:0050073 |
| ICD-11 | 1314810340 |
| SNOMED CT | 721798004 |
| UMLS | C0238013 |
| MedGen | 922866 |
| GARD | 0022735 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of pulmonary aspergilloma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › aspergillosis › pulmonary aspergilloma › invasive aspergillosis
Related subtypes (1): malt worker’s lung
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 53.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 26 |
| PHASE1 | 12 |
| PHASE3 | 6 |
| PHASE2 | 6 |
| PHASE4 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03717623 | PHASE4 | RECRUITING | Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants |
| NCT00334412 | PHASE4 | COMPLETED | COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis |
| NCT02646774 | PHASE4 | TERMINATED | Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis |
| NCT05101187 | PHASE3 | ACTIVE_NOT_RECRUITING | Olorofim Aspergillus Infection Study |
| NCT00158730 | PHASE3 | COMPLETED | Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment |
| NCT00163722 | PHASE3 | COMPLETED | A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients |
| NCT00836875 | PHASE3 | TERMINATED | A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children |
| NCT04876716 | PHASE3 | TERMINATED | Azole-echinocandin Combination Therapy for Invasive Aspergillosis |
| NCT05707832 | PHASE3 | COMPLETED | A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus |
| NCT00376337 | PHASE2 | TERMINATED | Micafungin Salvage Mono-therapy in Invasive Aspergillosis |
| NCT00404092 | PHASE2 | COMPLETED | Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis |
| NCT03327727 | PHASE2 | TERMINATED | VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults |
| NCT03816176 | PHASE2 | COMPLETED | A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants |
| NCT04218851 | PHASE2 | COMPLETED | Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) |
| NCT04225195 | PHASE2 | UNKNOWN | Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis |
| NCT01080651 | PHASE1 | COMPLETED | Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole |
| NCT02142153 | PHASE1 | COMPLETED | F901318 Single Ascending Dose Study in Healthy Male Volunteers |
| NCT02342574 | PHASE1 | COMPLETED | F901318 Multiple Ascending Dose Study |
| NCT02394483 | PHASE1 | COMPLETED | Single Ascending Oral Dose Study of F901318 |
| NCT02680808 | PHASE1 | COMPLETED | Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe |
| NCT02730442 | PHASE1 | COMPLETED | Study of Potential for Interaction of Fluconazole With F901318 |
| NCT02737371 | PHASE1 | COMPLETED | Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects |
| NCT02808741 | PHASE1 | COMPLETED | Evaluation of Immediate Release Tablet |
| NCT02912026 | PHASE1 | WITHDRAWN | Radiolabelled IV and Oral Metabolism Study of F901318 |
| NCT03076905 | PHASE1 | WITHDRAWN | Pharmacokinetics of IV Formulation |
| NCT03095547 | PHASE1 | WITHDRAWN | Drug/Drug Interactions With F901318 |
| NCT03340597 | PHASE1 | COMPLETED | Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects |
| NCT01386437 | Not specified | RECRUITING | Natural History of Individuals With Immune System Problems That Lead to Fungal Infections |
| NCT06069505 | Not specified | RECRUITING | Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study |
| NCT06583512 | Not specified | ACTIVE_NOT_RECRUITING | Treatment Duration of IPA |
| NCT00816088 | Not specified | COMPLETED | Diagnostic and Management Strategies for Invasive Aspergillosis |
| NCT00838643 | Not specified | UNKNOWN | Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
| NCT00843804 | Not specified | UNKNOWN | Surveillance for Nosocomial Infections in Pediatric Cancer Patients |
| NCT00982540 | Not specified | TERMINATED | Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients |
| NCT01128907 | Not specified | COMPLETED | Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients |
| NCT01176071 | Not specified | UNKNOWN | Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis |
| NCT01430663 | Not specified | COMPLETED | Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples |
| NCT01448226 | Not specified | COMPLETED | Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy |
| NCT01695499 | Not specified | UNKNOWN | Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates |
| NCT01695512 | Not specified | UNKNOWN | Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| POSACONAZOLE | 4 | 3 |
| VORICONAZOLE | 4 | 3 |
| AMPHOTERICIN B | 4 | 2 |
| CASPOFUNGIN | 4 | 2 |
| MICAFUNGIN | 4 | 2 |
| ANIDULAFUNGIN | 4 | 1 |
| ISAVUCONAZONIUM SULFATE | 4 | 1 |
| OLOROFIM | 3 | 9 |
| ISAVUCONAZOLE | 3 | 2 |
| PYRROLE | 3 | 1 |
| CHEMBL4750941 | 0 | 2 |
| CHEMBL499808 | 0 | 2 |
| CHEMBL3760049 | 0 | 1 |